Metabolomics—often referred to as the youngest of the omics—provides key insight into phenotype. However, bulk metabolomics requires the homogenization of the sample and is thus unable to discern metabolic differences at a cellular level.
Metabolomics—often referred to as the youngest of the omics—provides key insight into phenotype. However, bulk metabolomics requires the homogenization of the sample and is thus unable to discern metabolic differences at a cellular level.
Paradigm4’s REVEAL Integrative Analytics platform enables Alnylam Pharmaceuticals to discover novel, genetically-validated drug targets from population scale biobank genotype-phenotype datasets and underlies the extraordinary pace and productivity of Alnylam’s RNAi therapeutics pipeline.
More sensitive technology spurs proteomic and metabolomic biomarker identification, clinical use. (Complete article on page 21)
TetraScience, the R&D Data Cloud company, announced today that Paradigm4, an integrated scientific data analytics company, has joined the Tetra Partner Network (TPN) so that pharmaceutical customers can accelerate research decision-making using Tetra Data as a foundation for analytical computing.